Mononuclear phagocyte system blockade for enhanced liposome-assisted metabolic glycan labeling and circulating biomarker detection in mice

Pingping Feng, Tingbi Zhao, Rundong He, Lin Gan, Guangyu Hu, Xing Chen, Peng DaiNano 2026 · DOI

Abstract

The rapid clearance of nanoparticles by the mononuclear phagocyte system (MPS) severely compromises nanocarrier delivery efficiency and reduces the isolation yield of circulating biomarkers such as nucleosome-bound cell-free DNA (cfDNA) and exosomes. While liposome-based preconditioning is a promising strategy for transient MPS blockade, effective formulations remain scarce. Here, we report a potent MPS-blocking liposome (the Blocker) identified through an integrated screening strategy combining in vitro Kupffer cell uptake assays with in vivo biodistribution profiling. Notably, even upon co-administration, the Blocker effectively extended the circulation half-life of a widely used FDA‑approved PEGylated liposomal carrier by 2.1 folds, based on which liposome-assisted metabolic glycan labeling was significantly enhanced in a mouse tumor model. Furthermore, liposomal MPS blockade markedly inhibited the clearance of endogenous circulating cfDNA and exosomes, leading to a 6.8-fold increase in recovered cfDNA yield. This work highlighted liposomal blockade as a versatile platform for improving nanoparticle delivery and liquid biopsy sensitivity.

Introduction: The Clearance Challenge

A major hurdle in nanomedicine is ensuring that therapeutic agents remain in circulation long enough to reach their targets. The Mononuclear Phagocyte System (MPS), primarily composed of specialized macrophages called Kupffer cells in the liver, acts as a biological clearance mechanism, often removing over 99% of injected nanoparticles within minutes.

This rapid clearance has two significant drawbacks: it drastically reduces the therapeutic efficiency of drug-loaded nanocarriers and it creates "diagnostic blind spots" by removing natural biomarkers, such as cell-free DNA (cfDNA) and exosomes, which are essential for non-invasive "liquid biopsies."

Mechanism of MPS blockade in the liver sinusoid. The Blocker liposome saturates Kupffer cells, preventing the clearance of nanocarriers and endogenous biomarkers.

Designing the "Blocker" Liposome

To overcome this barrier, researchers developed a specialized "Blocker" liposome designed to temporarily saturate the liver's clearance capacity. Through an integrated screening of 18 different formulations, a specific non-PEGylated liposome composed of DOPC and Cholesterol (50:50 ratio) was identified as a potent decoy.

Unlike traditional "stealth" nanoparticles that use PEGylation to evade detection, this Blocker is designed to be highly attractive to Kupffer cells. The study found that lipid fluidity is a critical factor; liposomes with lower phase transition temperatures (more fluid) were internalized by Kupffer cells much more efficiently than rigid ones. By choosing DOPC over DSPC, the researchers created a particle that the liver's "vacuum cleaner" could not resist.

Key Results: Enhanced Delivery and Detection

The effectiveness of the Blocker was validated in two primary applications:

1. Improved Therapeutic Delivery

When co-administered with a standard PEGylated carrier, the Blocker extended the carrier's circulation half-life from 1.1 hours to 2.3 hours—a 2.1-fold increase. In a mouse tumor model, this translated to a 3.2-fold increase in the fluorescent signal for metabolic glycan labeling (LABOR), proving that more cargo successfully reached the tumor site.

2. Boosting Liquid Biopsy Sensitivity

The most striking results were observed in biomarker recovery. By inhibiting the clearance of endogenous cfDNA, the Blocker led to a 6.8-fold increase in the yield of DNA recovered from blood samples. Exosome recovery also saw a significant boost of approximately 1.5-fold. This suggests that MPS blockade could serve as a universal "pre-analytical enhancer" to improve the sensitivity of cancer detection from simple blood draws.

Conclusion and Future Outlook

This research highlights liposomal MPS blockade as a versatile and biocompatible platform for improving both nanoparticle delivery and liquid biopsy sensitivity. While the results in mice are promising, future work will need to address the long-term safety of temporary immune system blockade and the translation of these findings to human clinical settings. If successful, this "decoy" strategy could significantly enhance the efficacy of nanotherapies and the accuracy of early cancer diagnostics.

Summary updated

Abstract

The rapid clearance of nanoparticles by the mononuclear phagocyte system (MPS) severely compromises nanocarrier delivery efficiency and reduces the isolation yield of circulating biomarkers such as nucleosome-bound cell-free DNA (cfDNA) and exosomes. While liposome-based preconditioning is a promising strategy for transient MPS blockade, effective formulations remain scarce. Here, we report a potent MPS-blocking liposome (the Blocker) identified through an integrated screening strategy combining in vitro Kupffer cell uptake assays with in vivo biodistribution profiling. Notably, even upon co-administration, the Blocker effectively extended the circulation half-life of a widely used FDA‑approved PEGylated liposomal carrier by 2.1 folds, based on which liposome-assisted metabolic glycan labeling was significantly enhanced in a mouse tumor model. Furthermore, liposomal MPS blockade markedly inhibited the clearance of endogenous circulating cfDNA and exosomes, leading to a 6.8-fold increase in recovered cfDNA yield. This work highlighted liposomal blockade as a versatile platform for improving nanoparticle delivery and liquid biopsy sensitivity.
BibTeX
@inproceedings{feng2026mononuclear,
  author = {Pingping Feng and Tingbi Zhao and Rundong He and Lin Gan and Guangyu Hu and Xing Chen and Peng Dai},
  title = {{Mononuclear phagocyte system blockade for enhanced liposome-assisted metabolic glycan labeling and circulating biomarker detection in mice}},
  booktitle = {Nano},
  year = {2026},
  doi = {10.26599/nr.2026.94908501},
}
Figure